Peptides in the composition of Laennec that show antiviral effects in the therapy of atopic dermatitis and herpes infection



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A characteristic feature of atopic dermatitis is herpes infection, which necessitates application of antiviral therapy. The analysis of the peptide composition of Laennec drug by de novo mass spectrometric sequencing allowed us to identify over 10 peptides, characterized by potential antiviral effect at all stages of the viral life cycle. Laennec’s peptides can inhibit viral activation (inhibition of protein HCFC1), fusion of the viral envelope with the plasma membrane in the step of the host cell virus infection (inhibition of protein CD4), virus replication (inhibition of protein CTBP1), maturing of virion (inhibition of proteins CRM1, VPS4B, TPR, proline isomerase), budding of the viral particles from the cell membrane (inhibition of the NEDD4 protein). Laennek therapy in complex treatment of patients with atopic dermatitis and herpes virus infection can be substantiated by its pharmacologic activities including antiviral effect.

Full Text

Restricted Access

About the authors

I Yu Torshin

Laboratory of Pharmacoinformatics FRC Informatics and Control of the Russian Academy of Sciences

O A Gromova

Laboratory of Pharmacoinformatics FRC Informatics and Control of the Russian Academy of Sciences

Email: unesco.gromova@gmail.com

E A Dibrova

Medical Corporation RHANA

A N Gromov

Laboratory of Pharmacoinformatics FRC Informatics and Control of the Russian Academy of Sciences

O A Nazarenko

Ivanovo state medical Academy of Minzdrav of Russia

References

  1. Громова О, Торшин И, Гилельс А, Диброва Е, Гришина Т, Волков А и соавт. Препараты плаценты человека: фундаментальные и клинические исследования. Врач. 2014;(4):67-72 [Gromova O, Torshin I, Gilels A, Dibrova E, Grishina T, Volkov A et al. Human placental preparations: basic and clinical studies. Vrach. 2014;(4):67-72 (In Russ.)].
  2. Briguglio A. On 100 cases of surgical diseases treated with a cold-sterilized placental extract. Minerva Med. 1962;53:3118-3123.
  3. Shukla VK. A trial to determine the role of placental extract in the treatment of chronic non-healing wounds. J Wound Care. 2004;13:177-179.
  4. Caruselli M, Tigano F. Effect of Filatov’s placental extracts on some immunization phenomena. G Batteriol Immunol. 1953;46:15-23.
  5. Kludas M, Knoblauch R. Therapy of psoriasis with placental extract. Med Klin (Munich). 1952;47:1459-1461.
  6. Novikova ZI. Effect of placenta suspension on the immunologic indicators and dynamics of skin changes in patients with palmar and plantar pustulous psoriasis, Vestn Dermatol Venerol. 1985;10:46-48.
  7. Trebula J. Therapy of multiple sclerosis with placental extracts. Bratisl Lek Listy. 1952;32: 313-323.
  8. Dillon RN, Majnarich JJ. Placental extract in treatment of rheumatoid arthritis. Northwest Med. 1951;50:677-679.
  9. Burger G, Wenzel G. Therapy ofperipheral vascular disorders with placental extract. Med Klin (Munich). 1953;48:603-605.
  10. Kang SS, Woo SS, Im J, Yang JS, Yun CH, Ju HR et al. Human placenta promotes IL-8 expression through activation of JNK/SAPK and transcription factors NF-kappaB and AP-1 in PMA-differentiated THP-1 cells. Int Immunopharmacol. 2007;7:1488-1495.
  11. Robinson ES, McKhann CF. Immunological Application of Placental Extracts. Am J Public Health Nations Health. 1935;25:1353-1358.
  12. Торшин И, Волков А, Гилельс А, Керимкулова Н, Лиманова О, Федотова Л и соавт. Пептидный состав препарата плаценты человека «Лаеннек» и молекулярные механизмы его воздействия на организм человека. Эстетическая медицина. 2013;(1):33-45 [Torshin I, Volkov A, Gilel’s A, Kerimkulova N, Limanova O, Fedotova L et al. Peptidnyi sostav preparata platsenty cheloveka «Laennek» i molekulyarnye mekhanizmy ego vozdeistviya na organizm cheloveka. Esteticheskaya meditsina. 2013;(1):33-45 (In Russ.)].
  13. Елисютина ОГ, Феденко ЕС, Шабанова ИФ, Каримова ИМ. Первый опыт применения препарата Лаеннек («Japan bioproducts industry», Япония) при атопическом дерматите в России. Российский Аллергологический Журнал. 2010;(1):97-104 [Elisyutina OG, Fedenko ES, Shabanova IF, Karimova IM. The experience of atopic dermatitis treatment wit Laennek («Japan bioproducts industry co., ltd», Japan) in Russia. Russian Journal of Allergy. 2010;(1):97-104 (In Russ.)].
  14. Щербенко НБ. Атопический дерматит или нейродермит. Лечащий врач. 1998;(4):29-32 [Shcherbenko NB. Atopicheskii dermatit, ili neirodermit. Lechashchii vrach. 1998;(4):29-32 (In Russ.)].
  15. Зуйкова ИН, Шульженко АЕ, Щубелко РВ, Зуйков ИА, Каримова ИМ. Рецидивирующий генитальный герпес: стандартные подходы и новые перспективы терапии. Российский Аллергологический Журнал. 2014;(6):47-57 [Zuikova IN, Shulzhenko AE, Shchubelko RV, Zuikov IA, Karimova IM. Treatment of recurrent herpes virus infection: standard approaches and new perspectives. Russian Journal of Allergy. 2014;(6):47-57 (In Russ.)].
  16. Torshin IYu, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: Metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis. 2017;27:184-199.
  17. Torshin IYu, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Part 2: Density properties. Pattern Recognition and Image Analysis. 2016;26:483-496.
  18. Torshin IYu, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 1: Factorization approach. Pattern Recognition and Image Analysis. 2017;27:16-28.
  19. Yang J, Bogerd HP, Wang PJ, Page DC, Cullen BR. Two closely related human nuclear export factors utilize entirely distinct export pathways. Mol Cell. 2001;8:397-406.
  20. Hakata Y, Yamada M, Shida H. A multifunctional domain in human CRM1 (exportin 1) mediates RanBP3 binding and multimerization of human T-cell leukemia virus type 1 Rex protein. Mol Cell Biol. 2003;23:8751-8761.
  21. Shim S, Merrill SA, Hanson PI. Novel interactions of ES-CRT-III with LIP5 and VPS4 and their implications for ESCRT-III disassembly. Mol Biol Cell. 2008;19:2661-2672.
  22. Zeitlmann L, Sirim P, Kremmer E, Kolanus W. Cloning of ACP33 as a novel intracellular ligand of CD4. J Biol Chem. 2001;276:9123-9132.
  23. Lusso P, Secchiero P, Crowley RW, Garzino-Demo A, Berneman ZN, Gallo RC. CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus. Proc Natl Acad Sci USA. 1994;91:3872-3876.
  24. Vomastek T, Iwanicki MP, Burack WR, Tiwari D, Kumar D, Parsons JT et al. Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and docking domain on the nuclear pore complex protein Tpr cooperatively regulate ERK2-Tpr interaction. Mol Cell Biol. 2008;28:6954-6966.
  25. Bouamr F, Melillo JA, Wang MQ, Nagashima K, de Los Santos M, Rein A et al. PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101 [corrected]. J Virol. 2003;77:11882-11895.
  26. Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N et al. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci USA. 2008;105:8585-8590.
  27. Brazin KN, Mallis RJ, Fulton DB, Andreotti AH. Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. Proc Natl Acad Sci USA. 2002;99:1899-1904.
  28. Colgan J, Asmal M, Neagu M, Yu B, Schneidkraut J, Lee Y et al. Cyclophilin A regulates TCR signal strength in CD4+ T-cells via a proline-directed conformational switch in Itk. Immunity. 2004;21:189-201.
  29. Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, Jat P et al. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res. 2006;34:6126-6136.
  30. Subramanian T, Zhao LJ, Chinnadurai G. Interaction of CtBP with adenovirus E1A suppresses immortalization of primary epithelial cells and enhances virus replication during productive infection. Virology. 2013;443:313-320.
  31. Mazars R, Gonzalez-de-Peredo A, Cayrol C, Lavigne AC, Vogel JL, Ortega N et al. The THAP-zinc finger protein THAP1 associates with coactivator HCF-1 and O-GlcNAc transferase: a link between DYT6 and DYT3 dystonias. J Biol Chem. 2010;285:13364-13371.
  32. Misra V, Rapin N, Akhova O, Bainbridge M, Korchinski P. Zhangfei is a potent and specific inhibitor of the host cell factor-binding transcription factor Luman. J Biol Chem. 2005;280:15257-15266.
  33. Mahajan SS, Wilson AC. Mutations in host cell factor 1 separate its role in cell proliferation from recruitment ofVP16 and LZIP Mol Cell Biol. 2000;20:919-928.
  34. Kristie TM, Vogel JL, Sears AE. Nuclear localization of the C1 factor (host cell factor) in sensory neurons correlates with reactivation of herpes simplex virus from latency. Proc Natl Acad Sci USA. 1999;96:1229-1233.
  35. Narayanan A, Ruyechan WT, Kristie TM. The coactivator host cell factor-1 mediates Set1 and MLL1 H3K4 trimethylation at herpesvirus immediate early promoters for initiation of infection. Proc Natl Acad Sci USA. 2007;104:10835-10840.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2018



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies